Clinical Edge Journal Scan

Avoiding intensive chemotherapy due to older age alone is not advisable in mCRC


 

Key clinical point: Prognosis was similar among patients with metastatic colorectal cancer (mCRC) receiving intensive chemotherapy aged 80 years or older vs. those younger than 80 years. These findings do not recommend avoiding intensive chemotherapy for patients with mCRC only because of older age.

Major finding: Among patients who received intensive chemotherapy, the 5-year overall survival (OS) was comparable among those aged 80 years vs. those younger (13.6% vs. 21.4% ; P = .58). Moreover, age of 80 years and older was not an independent risk factor for OS (adjusted hazard ratio, 1.29; 95% confidence interval, 0.84-2.00).

Study details: Findings are from a population-based cohort study of 1,260 patients with mCRC. Patients were classified into those aged 80 years or older (n=234) or those younger than 80 years (n=1,026) during diagnosis.

Disclosures: There was no financial support for this research. The authors declared no conflicts of interest.

Source: Nakayama Y et al. Int J Clin Oncol. 2021 Jun 5. doi: 10.1007/s10147-021-01909-9 .

Recommended Reading

Clinical Edge Journal Scan Commentary: Colorectal Cancer July 2021
MDedge Hematology and Oncology
Continuation of screening endoscopy beyond age 75 prevents CRC incidence and death
MDedge Hematology and Oncology
Perioperative systemic therapy feasible and safe in patients with resectable colorectal peritoneal metastases
MDedge Hematology and Oncology
HLX04, an alternative biosimilar to bevacizumab for refractory/metastatic colorectal cancer
MDedge Hematology and Oncology
Cumulative social risk linked to reduced receipt of chemotherapy in patients with advanced CRC
MDedge Hematology and Oncology
Anlotinib substantially prolongs PFS in metastatic CRC
MDedge Hematology and Oncology
Obesity tied to increased risk for colorectal cancer in patients with Lynch syndrome
MDedge Hematology and Oncology
Dietary vitamin D intake tied to lower risk for colorectal cancer in patients at high CV risk
MDedge Hematology and Oncology
FTD/TPI effective and well tolerated in elderly patients with advanced colorectal cancer
MDedge Hematology and Oncology
Diagnostic efficacy of fecal immunochemical tests for assessment of suspected symptomatic CRC in primary care
MDedge Hematology and Oncology